Table of Contents Table of Contents
Previous Page  51 / 53 Next Page
Information
Show Menu
Previous Page 51 / 53 Next Page
Page Background

Phase I: 1L alectinib + atezolizumab

in

ALK

+ NSCLC

NCT02013219

51

Locally advanced or metastatic

ALK

+ NSCLC

Treatment naïve

ECOG PS 0–1

Tissue specimen available

(n=26–32)

Dose escalation

Starting doses:

Alectinib 600mg BID

+ atezolizumab (1,200mg IV q3w)

(n=6–12)

Dose expansion

Alectinib 600mg BID

+ atezolizumab (1,200mg IV q3w)

(n=20)

Phase Ib, multicentre, open-label trial

Primary endpoints

Safety

Recommended phase II dose

Secondary endpoints

PK

Immunogenic potential of atezolizumab